The discoveries of the pluripotent role of glycogen synthase kinase-3 (GSK-3) are pointing to GSK-3 as a potential target for therapy of neurodegenerative disorders and type 2 diabetes. GSK-3 is a constitutively active protein kinase that is inhibited in response to various extracellular signals. Lithium has been found to be an important inhibitor of GSK-3 activity and its use as a laboratory tool has contributed to the understanding of the role of GSK-3. Fluoride has been often used in study designs on GSK-3 as the inhibitor of protein phosphatases. Potential interactions of fluoride with the observed lithium effects are discussed.
Current Enzyme Inhibition aims to publish all the latest and outstanding developments in enzyme inhibition studies with regards to the mechanisms of inhibitory processes of enzymes, recognition of active sites, and the discovery of agonists and antagonists, leading to the design and development of new drugs of significant therapeutic value. Each issue contains a series of timely, in-depth reviews written by leaders in the field, covering a range of enzymes that can be exploited for drug development. Current Enzyme Inhibition is an essential journal for every pharmaceutical and medicinal chemist who wishes to have up-to-date knowledge about each and every development in the study of enzyme inhibition.